Preventing diseases with innovative products
As part of a set of interconditional transactions with GlaxoSmithKline Plc (GSK), Novartis divested its Vaccines business (excluding its influenza vaccines business), to GSK on March 2, 2015. In October 2014, Novartis announced that it had reached an agreement with CSL Limited to acquire the Novartis influenza vaccines business. The sale of the influenza vaccines business is expected to close by the end of 2015.
For more information on this transaction, click here.
The Novartis influenza vaccines business is among the world’s largest producers of influenza vaccines. Our products include: